De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Article Type: Distributed Content
Address Possible Security Lapses as Your Practice Returns to Normal
To accommodate patients remotely during the COVID-19 pandemic, practices may have expanded personnel access to protected health information and relied on devices that might be vulnerable to cyber attacks.
Proposed HIPAA Changes Promise to Improve Health Care Delivery
The Office for Civil Rights in the US Department of Health and Human Services announced proposed changes to strengthen patients’ rights to access their own health information, improve care coordination, and reduce regulatory burdens.
Lower Risk of CKD Stage Progression Found With Apixaban
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
Statins May Benefit Patients Receiving ADT for Relapsed Prostate Cancer
In a study, statin use was associated with a 36% decreased risk for death among men initiating androgen deprivation therapy for recurrent prostate cancer following primary or salvage radiation therapy.
New Guidelines for the Management of Lyme Disease
The Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology provided new clinical practice guidelines for Lyme disease prevention, diagnosis, and treatment.
Does Prior TKI Therapy Affect Outcomes in R/R AML Treated With Gilteritinib?
Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
Antileukemic Activity Seen With Flotetuzumab in Primary Induction Failure, Early-Relapse AML
Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.
Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM
A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
